<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01219959</url>
  </required_header>
  <id_info>
    <org_study_id>51067</org_study_id>
    <nct_id>NCT01219959</nct_id>
  </id_info>
  <brief_title>Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients</brief_title>
  <acronym>EDEN</acronym>
  <official_title>Multi-center, Prospective, Randomized Trial to Demonstrate Improved Metabolic Control of Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in the Treatment of Diabetic CAPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal,
      Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous
      Ambulatory Peritoneal Dialysis (CAPD) patients leads to improved metabolic control as
      measured by the magnitude of change from the baseline value in the HbA1c levels.

      Secondary Objectives: To demonstrate that use of glucose-sparing Peritoneal Dialysis
      solutions (D-E-N versus Dianeal only) in diabetic (Type 1 and Type 2) CAPD patients leads to
      lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic
      events requiring medical intervention, improved metabolic control, nutritional status, and
      Quality of Life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from the baseline value in HbA1c between the Dianeal, Extraneal, Nutrineal (D-E-N) group compared to the Dianeal only group.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic control medication usage</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic control</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <condition>Diabetes</condition>
  <condition>CAPD</condition>
  <arm_group>
    <arm_group_label>Non-glucose Sparing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dianeal only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose Sparing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dianeal, Extraneal, Nutrineal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dianeal</intervention_name>
    <description>Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose</description>
    <arm_group_label>Non-glucose Sparing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dianeal, Extraneal, Nutrineal</intervention_name>
    <description>Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin</description>
    <arm_group_label>Glucose Sparing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female patients 18 years of age or older

          2. Diagnosis of ESRD [Glomerular Filtration Rate (GFR) ≤ 15 mL/min]

          3. CAPD using only Dianeal, at least 1 exchange of 2.5% or 4.25% dextrose/day, no
             prescribed dry time

          4. Diabetes Mellitus (Type 1 and 2)

          5. HbA1c &gt; 6.0% but ≤ 12.0%

          6. Blood hemoglobin ≥ 8.0 g/dL, but ≤ 13.0 g/dL

          7. Total Kt/V ≥ 1.7

        Exclusion Criteria:

          1. Blood Urea Nitrogen (BUN) &gt; 95 mg/dL

          2. Exposure to Extraneal within 60 days of Screening

          3. Mean Arterial Pressure (MAP) ≥ 125 mm Hg, or volume depleted (MAP &lt; 77mm Hg) at
             Screening

          4. Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30
             days

          5. Cardiovascular event within the last 30 days

          6. Ongoing clinically significant congestive heart failure [New York Heart Association
             (NYHA) class III or IV]

          7. Allergy to starch-based polymers, glycogen storage disease or isomaltose/maltose
             intolerance

          8. Receiving rosiglitazone maleate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call central contact for information</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nefrosalud Ltda</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Barranquila</name>
      <address>
        <city>Barranquila</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Soledad</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rts Ltda Ag H.U.S</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda H.U.V</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda STR del Valle</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Versalles</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Therapy Services (RTS) Ltda Cartagena</name>
      <address>
        <city>Cartagena</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Cucuta</name>
      <address>
        <city>Cucuta</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Girardot</name>
      <address>
        <city>Girardot</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Renal de Tolima</name>
      <address>
        <city>Ibague</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Sucursal Medellin</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Valle de Aburra</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Sogamoso</name>
      <address>
        <city>Sogamoso</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Sucrusal Tulua</name>
      <address>
        <city>Tulua</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTS Ltda Villavicencio</name>
      <address>
        <city>Villavicencio</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESRD</keyword>
  <keyword>Diabetes</keyword>
  <keyword>CAPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Icodextrin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 14, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

